Generated by AI
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes. The company also advances additional candidates across autoimmune, fibrotic, and cancer-related areas, including programs targeting ulcerative colitis, vitiligo, multiple sclerosis, and solid tumors. Through its proprietary chemistry and immunology expertise, Nektar Therapeutics develops highly selective therapeutic candidates intended to modulate key biological pathways and support precision treatment approaches across specialty disease areas.
Website455 Mission Bay Boulevard South
San Francisco, CA, 94158
United States
The latest articles about NKTR.
Nektar beats Q3 earnings estimates with a narrower-than-expected loss, but lower 2026 revenue guidance sends shares down 4.5%.
Summary of Oct 12's posts. Generated by AI.
Summary of Oct 1's posts. Generated by AI.
Summary of Jun 25's posts. Generated by AI.
Summary of Oct 5's posts. Generated by AI.
Investors talking about NKTR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.